Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis

Ann Clin Microbiol Antimicrob. 2017 Aug 14;16(1):54. doi: 10.1186/s12941-017-0230-0.

Abstract

Objective: Helicobacter pylori (H. pylori) eradication rarely develops into antibiotic-associated hemorrhagic colitis (AAHC), in which the etiology of colitis remains unclear. We herein report a rare case of AAHC caused by second-line therapy for H. pylori eradication.

Results: A 65-year-old female was administered second-line therapy for H. pylori composed of 1500 mg of amoxicillin, 500 mg of metronidazole and 40 mg of vonoprazan for 7 days because of first-line therapy failure. A day after completing second-line therapy, she complained of abdominal pain and hematochezia. Colonoscopy revealed a hemorrhage and edematous mucosa with no transparent vascular pattern in the transverse colon. A bacterial culture detected Klebsiella oxytoca (K. oxytoca), but no other pathogenic bacteria. A drug-induced lymphocyte stimulation test (DLST) showed positive reactions for both amoxicillin and metronidazole. According to these findings, the patient was diagnosed with AAHC. Bowel rest for 6 days relieved her abdominal pain and hematochezia.

Conclusions: The present case developed AAHC caused by second-line therapy for H. pylori eradication. The pathogenesis is considered to be associated with microbial substitution as well as a delayed-type allergy to antibiotics, suggesting that AAHC is a potential adverse event of second-line therapy for H. pylori eradication.

Publication types

  • Case Reports

MeSH terms

  • Abdominal Pain
  • Aged
  • Amoxicillin / adverse effects*
  • Amoxicillin / therapeutic use
  • Biopsy
  • Colitis / diagnostic imaging
  • Colitis / etiology*
  • Colitis / microbiology
  • Colitis / physiopathology
  • Colon / diagnostic imaging
  • Colon / drug effects*
  • Colonoscopy
  • Female
  • Gastrointestinal Hemorrhage
  • Helicobacter Infections / complications*
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori / pathogenicity*
  • Hemorrhage
  • Humans
  • Klebsiella oxytoca
  • Metronidazole / adverse effects*
  • Metronidazole / therapeutic use
  • Mucous Membrane / pathology
  • Pyrroles / adverse effects*
  • Pyrroles / therapeutic use
  • Rare Diseases
  • Sulfonamides / adverse effects*
  • Sulfonamides / therapeutic use

Substances

  • 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
  • Pyrroles
  • Sulfonamides
  • Metronidazole
  • Amoxicillin